Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114436 | 0.80 | MAPK1 (0.65) | ALDH1A1SMN1; SMN2TSHRKMT2ALMNA | |
| SCHEMBL6598206 | 0.78 | TRPV4 (0.43) | ALDH1A1SMN1; SMN2HTTTSHRMEN1 | |
| SCHEMBL9632623 | 0.77 | TSHR (0.69) | ALDH1A1SMN1; SMN2HTTUBE2NRXFP1 | |
| SCHEMBL6598078 | 0.75 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2HTTTSHRMEN1 | |
| SCHEMBL6595891 | 0.75 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2HTTRXFP1TSHR | |
| SCHEMBL11919283 | 0.74 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2UBE2NRXFP1TSHR | |
| SCHEMBL3997775 | 0.73 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTTSHRKMT2A | |
| SCHEMBL5489263 | 0.73 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL29463785 | 0.73 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL3996272 | 0.72 | TSHR (0.59) | ALDH1A1SMN1; SMN2HTTTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | disclosed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | disclosed |
| EP-1280802-A4 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2003-06-11 | — | — | EP | disclosed |
| EP-1280802-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085726-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | CCNA1, CCNI, CCNT1 | ALDH1A1 543/4885SMN1; SMN2 4291/4885HTT 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.